Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns positive

Q1 FY2026 capital expenditures was $0, compared with -$31K a year earlier. Trailing-twelve-month capital expenditures was -$3K. Over 3 fiscal years it compounded at -37.0% a year.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$750.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
-$34K-76.1% YoY
LTMMar 2026
-$3K-97.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-76.1%——
3-year CAGR-37.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(34K) USD
Year-over-year change
+76.1%

Capital Expenditures vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 capital expenditures of $3K is the 2nd largest of the 3 companies compared; the peer median is $618K.
  • Its year-over-year change of -97.1% is the lowest of 2, against a peer median of +4.2%.
  • Capital expenditures amounts to 0.0% of revenue for IRWD, versus a peer median of 0.1%.
IRWD Competitors Peer median
Capital Expenditures for IRWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$1.24M +4.2%+200.5%0.3%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$3K -97.1%-37.0%0.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding IRWD) $618K+4.2%+200.5%0.1%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.45M175.07M(1B)880K24.02M
Depreciation & Amortization1.5M1.42M1.58M2.01M1.88M
Deferred Income Tax(333.29M)65.74M72.64M68.09M40.8M
Stock-Based Compensation22.28M27.05M32.01M29.85M17.25M
Change in Working Capital17.73M2.82M11.28M739K39.65M
Accounts Receivables7.71M7.99M924K47.24M35.15M
Inventory00000
Accounts Payables(2.64M)(8.12M)12.38M(20.21M)6.2M
Other Working Capital12.66M2.94M(2.03M)(26.29M)(1.7M)
Other Non-Cash Items25.23M1.67M1.07B1.98M3.45M
Operating Cash Flow261.9M273.76M183.43M103.55M127.04M
Capital Expenditures(265K)(136K)(273K)(142K)(34K)
Acquisitions (Net)00(1.03B)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(265K)(136K)(1.03B)(142K)(34K)
Debt Repayment0(120.7M)300M(115M)0
Common Stock Issued19.58M9.54M6.36M11.01M216K
Common Stock Repurchased(24.13M)(126.39M)000
Dividends Paid00000
Other Financing Activities19.58M9.54M(29.2M)(2.98M)0
Financing Cash Flow(4.55M)(237.55M)277.16M(106.97M)216K
Effect of Forex Changes00(53K)(32K)(329K)
Net Change in Cash257.08M36.07M(565.78M)(3.6M)126.9M
Free Cash Flow261.63M273.63M183.15M103.41M127.01M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.